Cerus Corporation Announces Pricing of Upsized Public Offering of Common Stock
January 29 2020 - 9:00AM
Business Wire
Cerus Corporation (Nasdaq: CERS) announced today the pricing of
a registered underwritten public offering of its common stock for
proceeds of approximately $55.0 million, before deducting estimated
offering expenses payable by Cerus. The offering is expected to
close January 31, 2020, subject to customary closing conditions.
All of the shares sold in the offering were sold by Cerus. In
addition, Cerus has granted the underwriter a 30-day option to
purchase up to an additional $8.25 million of shares of its common
stock. On January 28, 2020, the last sale price of the shares as
reported on The Nasdaq Global Market was $4.15 per share.
BTIG, LLC is acting as sole book-running manager for the
offering.
A shelf registration statement on Form S-3 (File No. 333-219727)
relating to the shares of common stock described above was
previously filed by Cerus with the Securities and Exchange
Commission ("SEC") and declared effective on January 8, 2018. This
offering is being made solely by means of a prospectus supplement
and accompanying prospectus included in the registration statement.
A final prospectus supplement and accompanying prospectus relating
to the offering will be filed with the SEC and will be available on
the SEC's website located at http://www.sec.gov. Alternatively,
copies of the final prospectus supplement, when available, and the
accompanying prospectus may be obtained by contacting BTIG, LLC at
65 East 55th Street, New York, NY, 10022, by email at
equitycapitalmarkets@btig.com or by telephone at (212)
593-7555.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any
such state or jurisdiction.
About Cerus
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply. Based in Concord, California, Cerus develops
and markets the INTERCEPT Blood System. Cerus currently markets and
sells the INTERCEPT Blood System in the United States, Europe, the
Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world.
Forward Looking Statements
This press release contains forward-looking statements. Any
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements,
including, without limitation, statements relating to Cerus’ public
offering. These forward-looking statements are based upon Cerus’
current expectations. Actual results could differ materially from
these forward-looking statements as a result of certain factors,
including, without limitation, risks related to market conditions
and the satisfaction of customary closing conditions related to the
public offering, risks related to the application of the net
proceeds from the public offering, risks associated with the
uncertain research and product development process, and other risks
detailed in Cerus' filings with the SEC, including in Cerus'
quarterly report on Form 10-Q for the quarter ended September 30,
2019, filed with the SEC on October 30, 2019 and in the preliminary
prospectus supplement related to the public offering filed with the
SEC on January 28, 2020. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. Cerus does not undertake any
obligation to update any forward-looking statements as a result of
new information, future events, changed assumptions or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200129005266/en/
Tim Lee – Investor Relations Director Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Sep 2023 to Sep 2024